Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238416 | 0.81 | CHRM2 (0.38) | HCRTR2HCRTR1SLC6A7 | |
| SCHEMBL25279880 | 0.80 | CHRM2 (0.38) | HCRTR2HCRTR1SLC6A7 | |
| SCHEMBL25279879 | 0.80 | CHRM2 (0.38) | HCRTR2HCRTR1SLC6A7 | |
| SCHEMBL27233812 | 0.76 | ACACB (0.41) | SLC6A7 | |
| SCHEMBL27233744 | 0.76 | ACACB (0.41) | SLC6A7 | |
| SCHEMBL29165971 | 0.76 | ACACB (0.41) | SLC6A7 | |
| SCHEMBL26090067 | 0.75 | HCRTR2 (0.44) | HCRTR2HCRTR1SLC6A7ALDH1A1POLB | |
| SCHEMBL26086786 | 0.75 | HCRTR2 (0.43) | HCRTR2HCRTR1SLC6A7KDM4EALDH1A1 | |
| SCHEMBL26089752 | 0.75 | HCRTR2 (0.43) | HCRTR2HCRTR1SLC6A7KDM4EALDH1A1 | |
| SCHEMBL15285931 | 0.75 | SLC6A7 (0.66) | HCRTR2HCRTR1SLC6A7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HCRTR2 183/4885HCRTR1 210/4885SLC6A7 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.